New hope for stubborn Tick-Borne infection in vulnerable patients

This program provides access to an experimental drug called tafenoquine for immunocompromised adults who have a persistent Babesia infection that hasn't cleared with standard treatments. Patients take the drug orally, starting with daily doses and then switching to weekly doses, continuing until tests show the parasite is gone and symptoms have resolved. The goal is to control this serious infection in people whose weakened immune systems put them at higher risk.